Antlia Bioscience, Inc.

Antlia Bioscience is an active biopharmaceutical company founded in 2020 based in California focusing on developing novel long-lasting synthetic peptide therapeutics targeting chronic cardiometabolic diseases such as resistant hypertension, pulmonary arterial hypertension, chronic heart failure, and lung diseases. Their pipeline includes multiple preclinical-stage programs advancing toward IND applications. The company was co-founded by Brian L. Johnson and Nigel Shankley. It operates primarily out of San Diego/Encinitas area with a strong emphasis on innovative peptide platforms aimed at improving treatment options for cardiovascular and metabolic disorders.